Your email has been successfully added to our mailing list.

×
0.00376411543287328 0.00622526783129038 0.00897596757069788 0.00361934176237815 0.0194479297365119 0.056775407779172 0.0716147090049223 0.0523839397741532
Stock impact report

Reata Pharma up 11% on potential acquisition interest [Seeking Alpha]

Reata Pharmaceuticals, Inc. - Class A (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com
Company Research Source: Seeking Alpha
Reata Pharmaceuticals ( RETA +10.9% AMGN -3.9% Reata's lead candidate is bardoxolone methyl, in late-stage development for a kidney disorder called Alport syndrome, connective tissue disease-pulmonary arterial hypertension and focal segmental glomerulosclerosis. Another late-stage candidate is omaveloxolone for a degenerative neuromuscular disorder called Friedreich's ataxia. Show less Read more
Impact Snapshot
Event Time:
RETA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RETA alerts
Opt-in for
RETA alerts

from News Quantified
Opt-in for
RETA alerts

from News Quantified